Literature DB >> 4955122

Autoimmune encephalomyelitis and ocular lesions in monkeys sensitized during the neonatal period.

S H Stone, E M Lerner, R E Myers, W H Niemann.   

Abstract

The neonatal rhesus monkey is susceptible to the induction of autoimmune encephalomyelitis. The disease has been produced regularly by injection of neonatal animals with guinea pig spinal cord antigen in complete Freund's adjuvant. The onset of the disease, as compared with onset in adults, is delayed and is most often heralded by intrinsic eye lesions, notably widespread retinal hemorrhages.

Entities:  

Mesh:

Year:  1966        PMID: 4955122     DOI: 10.1126/science.151.3709.473

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  6 in total

1.  [Experimental allergic chorioretinitis in rabbits by immunization to homologous retina in adjuvant. I. Clinical studies (author's transl)].

Authors:  K D Schröder; W Meyer; E Hempel; S Tilgner
Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol       Date:  1974

Review 2.  Hyperacute, neutrophilic, and localized forms of experimental allergic encephalomyelitis: a review.

Authors:  S Levine
Journal:  Acta Neuropathol       Date:  1974       Impact factor: 17.088

3.  Correlative studies on experimental allergic uveo-retinal disease.

Authors:  R Macdonald
Journal:  Trans Am Ophthalmol Soc       Date:  1971

4.  A new form of localized allergic encephalomyelitis featuring polymorphonuclear neutrophilic leukocytes.

Authors:  S Levine; E M Hoenig
Journal:  Am J Pathol       Date:  1971-07       Impact factor: 4.307

5.  Chronic relapsing EAE. Time course of neurological symptoms and pathology.

Authors:  H Lassmann; H M Wisniewski
Journal:  Acta Neuropathol       Date:  1978-08-07       Impact factor: 17.088

6.  Chronic relapsing experimental allergic encephalomyelitis: effect of age at the time of sensitization on clinical course and pathology.

Authors:  H Lassmann; H M Wisniewski
Journal:  Acta Neuropathol       Date:  1979-07-13       Impact factor: 17.088

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.